ATE437641T1 - Verfahren zur herstellung von medikamenten zur verringerung der amyloid-abscheidung, amyloid- neurotoxizität und mikrogliosis - Google Patents

Verfahren zur herstellung von medikamenten zur verringerung der amyloid-abscheidung, amyloid- neurotoxizität und mikrogliosis

Info

Publication number
ATE437641T1
ATE437641T1 AT04752432T AT04752432T ATE437641T1 AT E437641 T1 ATE437641 T1 AT E437641T1 AT 04752432 T AT04752432 T AT 04752432T AT 04752432 T AT04752432 T AT 04752432T AT E437641 T1 ATE437641 T1 AT E437641T1
Authority
AT
Austria
Prior art keywords
amyloid
microgliosis
reducing
animals
neurotoxicity
Prior art date
Application number
AT04752432T
Other languages
English (en)
Inventor
Michael Mullan
Daniel Paris
Original Assignee
Roskamp Res Llc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=33551420&utm_source=***_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=ATE437641(T1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Roskamp Res Llc filed Critical Roskamp Res Llc
Application granted granted Critical
Publication of ATE437641T1 publication Critical patent/ATE437641T1/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Neurosurgery (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Epidemiology (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Steroid Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Hydrogenated Pyridines (AREA)
AT04752432T 2003-05-15 2004-05-17 Verfahren zur herstellung von medikamenten zur verringerung der amyloid-abscheidung, amyloid- neurotoxizität und mikrogliosis ATE437641T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US47069403P 2003-05-15 2003-05-15
PCT/US2004/015417 WO2004110354A2 (en) 2003-05-15 2004-05-17 Method for reducing amyloid deposition, amyloid neurotoxicity and microgliosis

Publications (1)

Publication Number Publication Date
ATE437641T1 true ATE437641T1 (de) 2009-08-15

Family

ID=33551420

Family Applications (1)

Application Number Title Priority Date Filing Date
AT04752432T ATE437641T1 (de) 2003-05-15 2004-05-17 Verfahren zur herstellung von medikamenten zur verringerung der amyloid-abscheidung, amyloid- neurotoxizität und mikrogliosis

Country Status (11)

Country Link
US (1) US7732467B2 (de)
EP (1) EP1628663B1 (de)
JP (1) JP4971794B2 (de)
CN (1) CN100444840C (de)
AT (1) ATE437641T1 (de)
CA (1) CA2525970C (de)
DE (1) DE602004022284D1 (de)
DK (1) DK1628663T3 (de)
ES (1) ES2334029T3 (de)
HK (1) HK1092358A1 (de)
WO (1) WO2004110354A2 (de)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1858325A4 (de) * 2005-01-07 2010-06-30 Roskamp Res Llc Verbindungen zur hemmung der beta-amyloidproduktion und verfahren zum identifizieren dieser verbindungen
WO2006109164A2 (en) * 2005-04-15 2006-10-19 Research & Innovation Soc. Coop. A R.L. A method for preventing, delaying or reverting abnormal amyloid deposition
WO2007103683A2 (en) * 2006-03-01 2007-09-13 Roskamp Research Llc Compounds for inhibiting beta-amyloid production
US20100119599A1 (en) * 2006-12-08 2010-05-13 Archer Pharmaceuticals, Inc. Polyhydroquinoline compounds and dihydropyridine compounds for inhibiting beta-amyloid production
US8709394B2 (en) * 2007-09-28 2014-04-29 Ndsu Research Foundation Antimicrobial polysiloxane materials containing metal species
WO2009046338A1 (en) * 2007-10-05 2009-04-09 Roskamp Research Llc Method for increasing cerebral blood flow with (+)-nilvadipine enantiomer
DK2214666T3 (da) * 2007-10-05 2014-01-27 Alzheimer S Inst Of America Inc Fremgangsmåde til reducering af amyloid-afsætning, amyloid-neurotoksicitet og mikrogliose med (-)-nilvadipin-enantiomer
US20100093810A1 (en) * 2007-10-05 2010-04-15 Alzheimer's Institute Of America, Inc. Pharmaceutical Compositions for Reducing Amyloid Deposition, Amyloid Neurotoxicity, and Microgliosis
US20100292281A1 (en) * 2009-05-15 2010-11-18 The University Of Kentucky Research Foundation Treatment of mci and alzheimer's disease
EP2311823A1 (de) * 2009-10-15 2011-04-20 AC Immune S.A. 2,6-Diaminopyridinverbindungen zur Behandlung von Krankheiten im Zusammenhang mit Amyloidproteinen oder zur Behandlung von Augenkrankheiten
KR20140128229A (ko) * 2013-04-26 2014-11-05 한국과학기술연구원 체내 단백질 응집체의 용해를 이용한 단백질의 비정상적인 응집 또는 미스폴딩과 관련된 질환 또는 질병을 진단하는 혈액진단키트

Family Cites Families (52)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4338322A (en) * 1975-07-02 1982-07-06 Fujisawa Pharmaceutical Co., Ltd. 1,4-Dihydropyridine derivatives, pharmaceutical compositions containing same and methods of effecting vasodilation using same
JPS6038322A (ja) * 1983-08-11 1985-02-27 Fujisawa Pharmaceut Co Ltd ジヒドロピリジンａ物質含有易溶性固形製剤
JPS61129140A (ja) 1984-11-27 1986-06-17 Nitto Electric Ind Co Ltd 医薬組成物
GB8431119D0 (en) * 1984-12-10 1985-01-16 Fujisawa Pharmaceutical Co Anti-arteriosclerotic composition
US4940556A (en) 1986-01-30 1990-07-10 Syntex (U.S.A.) Inc. Method of preparing long acting formulation
US5114946A (en) * 1987-06-12 1992-05-19 American Cyanamid Company Transdermal delivery of pharmaceuticals
ATE84714T1 (de) 1987-06-12 1993-02-15 American Cyanamid Co Transkutane verabreichung von pharmazeutika.
US4992445A (en) * 1987-06-12 1991-02-12 American Cyanamid Co. Transdermal delivery of pharmaceuticals
US5001139A (en) * 1987-06-12 1991-03-19 American Cyanamid Company Enchancers for the transdermal flux of nivadipine
US5045553A (en) * 1987-06-24 1991-09-03 Fujisawa Pharmaceutical Company, Ltd. Pharmaceutical composition for percutaneous drug absorption and percutaneous drug absorption promoter
US4820720A (en) * 1987-08-24 1989-04-11 Alza Corporation Transdermal drug composition with dual permeation enhancers
ATE76292T1 (de) 1987-11-25 1992-06-15 American Cyanamid Co System fuer die verzoegerte (kontrollierte) freisetzung von substituierten dihydropyridincalciumantagonisten.
US5160734A (en) * 1987-11-25 1992-11-03 American Cyanamid Company Sustained release delivery system for substituted dihydropyridine calcium channel blockers
US4902514A (en) * 1988-07-21 1990-02-20 Alza Corporation Dosage form for administering nilvadipine for treating cardiovascular symptoms
WO1990011761A1 (en) * 1989-03-31 1990-10-18 The Children's Medical Center Corporation Treatment of aids dementia, myelopathy and blindness
JP2867462B2 (ja) 1989-09-12 1999-03-08 藤沢薬品工業株式会社 経皮吸収用製剤
JPH03117658A (ja) 1989-09-29 1991-05-20 Mazda Motor Corp 外燃式ロータリピストンエンジン
JP2920956B2 (ja) 1989-10-06 1999-07-19 藤沢薬品工業株式会社 ニルバジピン含有持続性錠剤
WO1992003137A1 (en) 1990-08-23 1992-03-05 The Children's Medical Center Corporation Treatment of aids dementia, myelopathy, peripheral neuropathy, and vision loss
WO1993005770A1 (en) 1991-09-20 1993-04-01 Fujisawa Pharmaceutical Co., Ltd. Long-acting preparation
JPH05139974A (ja) 1991-11-26 1993-06-08 Fujisawa Pharmaceut Co Ltd ジヒドロピリジンａ物質含有易溶性固体分散体の製造法
DE4141646A1 (de) 1991-12-17 1993-06-24 Klinge Co Chem Pharm Fab Arzneimittelkombination mit synergistischer wirkung, verfahren zu seiner herstellung und seine verwendung
US5340591A (en) * 1992-01-24 1994-08-23 Fujisawa Pharmaceutical Co., Ltd. Method of producing a solid dispersion of the sparingly water-soluble drug, nilvadipine
DE4229805A1 (de) 1992-09-07 1994-03-24 Werner E G Prof Dr Mueller Kalzium-Kanal-Antagonisten oder deren Derivate zur Herstellung eines Arzneimittels zur Bekämpfung von Erkrankungen, die durch Prion-Proteine oder Prion-analoge Proteine ausgelöst werden
CA2125251C (en) 1993-06-07 2005-04-26 Yoshiyuki Inada A pharmaceutical composition for angiotensin ii-mediated diseases
US5721263A (en) * 1993-06-07 1998-02-24 Takeda Chemical Industries, Ltd. Pharmaceutical composition for angiotensin II-mediated diseases
US6334997B1 (en) * 1994-03-25 2002-01-01 Isotechnika, Inc. Method of using deuterated calcium channel blockers
EP0911027A4 (de) * 1996-04-26 2000-11-29 Fujisawa Pharmaceutical Co Mittel die dihydropyridine enthalten zur verbesserung der durchblutung der augenumgebenden gewebe
US6271259B1 (en) * 1996-05-07 2001-08-07 Ito En, Ltd. Method for improving the brain function, inhibiting glutamate excitotoxicity and rescuing from neuronal death
KR100222306B1 (ko) 1996-11-20 1999-10-01 이병언 닐바디핀 속효성 고형제제 및 이의 제조방법
EP1085879A2 (de) 1998-06-08 2001-03-28 Advanced Medicine, Inc. Mehrfachbindende mittel die den 5-ht transporter modulieren
JP2002517440A (ja) 1998-06-08 2002-06-18 アドバンスド メディスン インコーポレーテッド 新規カルシウムチャンネル薬物および用途
SG142116A1 (en) 1998-07-10 2008-05-28 Novartis Ag Antihypersensitive combination of valsartan and calcium channel blocker
EP1260232A1 (de) 2000-03-03 2002-11-27 Fujisawa Pharmaceutical Co., Ltd. Heilmittel für die behandlung von bösartigen-tumorassoziierten neurosen und azoor-viralen oder analogen erkrankungen
CZ301790B6 (cs) 2000-04-11 2010-06-23 Sankyo Company Limited Farmaceutický prípravek obsahující blokátor vápníku
JP2001335483A (ja) 2000-05-30 2001-12-04 Nichiko Pharmaceutical Co Ltd ニルバジピン含有製剤
AU2001278045B2 (en) * 2000-07-27 2006-08-03 Pharmacia Corporation Epoxy-steroidal aldosterone antagonist and calcium channel blocker combination therapy for treatment of congestive heart failure
JP3968687B2 (ja) 2000-09-13 2007-08-29 東和薬品株式会社 易吸収性ニルバジピン錠
JP3470096B2 (ja) 2000-09-19 2003-11-25 沢井製薬株式会社 ニルバジピン含有易溶性固形製剤およびその製造法
MXPA03005393A (es) * 2000-12-19 2003-09-25 Merck Patent Gmbh Formulacion farmaceutica que contiene pirazolo (4,3-d) pirimidinas y antitromboticos, antagonistas de calcio, prostaglandinas o derivados de prostaglandina.
KR20030059351A (ko) * 2000-12-19 2003-07-07 메르크 파텐트 게엠베하 티에노피리미딘 및 항혈전제, 칼슘 길항제,프로스타글란딘 또는 프로스타글란딘 유도체를 포함하여이루어지는 약제학적 조성물
US7083642B2 (en) * 2000-12-22 2006-08-01 Avantec Vascular Corporation Delivery of therapeutic capable agents
CA2333494A1 (en) * 2001-02-01 2002-08-01 Vasogen Ireland Limited Blood brain barrier modulation
WO2002096415A2 (en) 2001-05-25 2002-12-05 Schering Corporation Use of azetidinone substituted derivatives in the treatment of alzheimer's disease
AU2003298514A1 (en) * 2002-05-17 2004-05-04 Eisai Co., Ltd. Methods and compositions using cholinesterase inhibitors
NZ536555A (en) 2002-05-17 2007-03-30 Novartis Ag Pharmaceutical composition comprising a renin inhibitor, a calcium channel blocker and a diuretic
TW200306799A (en) 2002-05-17 2003-12-01 Novartis Ag Combination of organic compounds
EG24716A (en) 2002-05-17 2010-06-07 Novartis Ag Combination of organic compounds
JP2003146878A (ja) 2002-11-22 2003-05-21 Sawai Pharmaceutical Co Ltd ニルバジピン含有易溶性固形製剤およびその製造法
BR0317747A (pt) * 2002-12-24 2005-11-22 Neurochem Int Ltd Método de tratamento terapêutico concomitante de um indivìduo, composição farmacêutica, kit, uso de um primeiro agente e um segundo agente, e, métodos de prevenir ou tratar uma doença relacionada com amilóide-b, doença de alzheimer e insuficiência cognitiva suave
US20050031651A1 (en) * 2002-12-24 2005-02-10 Francine Gervais Therapeutic formulations for the treatment of beta-amyloid related diseases
JP2004002460A (ja) 2003-07-29 2004-01-08 Towa Yakuhin Kk 易吸収性ニルバジピン錠の製造法

Also Published As

Publication number Publication date
HK1092358A1 (en) 2007-02-09
JP2007501277A (ja) 2007-01-25
EP1628663A4 (de) 2006-05-24
WO2004110354A3 (en) 2005-02-10
US20050009885A1 (en) 2005-01-13
EP1628663A2 (de) 2006-03-01
CN100444840C (zh) 2008-12-24
ES2334029T3 (es) 2010-03-04
DK1628663T3 (da) 2010-03-08
EP1628663B1 (de) 2009-07-29
CA2525970A1 (en) 2004-12-23
JP4971794B2 (ja) 2012-07-11
DE602004022284D1 (de) 2009-09-10
WO2004110354A2 (en) 2004-12-23
CA2525970C (en) 2011-03-22
CN1809352A (zh) 2006-07-26
US7732467B2 (en) 2010-06-08

Similar Documents

Publication Publication Date Title
HK1092358A1 (en) Method for producing medicaments for reducing amyloid deposition, amyloid neurotoxicity and microgloisis
ATE355374T1 (de) Therapeutische agentien und methoden ihrer verwendung zur behandlung von amyloidogenen erkrankungen
DE60216830D1 (de) Pharmazeutische Zusammensetzungen zur Behandlung von Störungen des ZNS oder anderen Erkrankungen
DE69533040D1 (de) Medikamente zur vorbeugung oder behandlung von vaskulären hämorrhagien
ATE401395T1 (de) Verfahren zur behandlung neurodegenerativer, psychiatrischer und anderer störungen mit deacetylaseinhibitoren
ATE409176T1 (de) 1-phenylalkancarbonsäurederivate zur behandlung neurodegenerativer erkrankungen
ATE412415T1 (de) Inhibitoren der phosphodiesterase der zyklischen nucleotiden, mit einer benzodiazepinischen struktur, und deren verwendung in therapie
UY28011A1 (es) Compuestos de tiazol para el tratamiento de trastornos neurodegenerativos
ATE399553T1 (de) Pharmazeutische zusammensetzungen mit dextromethorphan und chinidin zur behandlung von neurologischen erkrankungen
DE69938653D1 (de) Isolierte stromalzellen zur verwendung in der behandlung von erkrankungen des zentralnervensystems
BRPI0712322A2 (pt) compostos e combinações destes para a inibição da produção de beta-amilóide e métodos de uso dos mesmos
ATE451368T1 (de) Azabicyclische verbindungen zur linderung von schmerzen und zur behandlung von erkrankungen des zentralen nervensystems
MX2021015499A (es) Derivados de 2h-indazol y su uso en el tratamiento de enfermedades.
MX2021015498A (es) Derivados de imidazo[1,2-a]piridinilo y su uso en el tratamiento de enfermedades.
WO2010018996A3 (ko) 인간 신경줄기세포 및 이를 이용한 중추 또는 말초 신경계 질환 및 손상 치료용 약학적 조성물
DE60312505D1 (de) Injektion aus ixeris sonchifolia zur behandlung von kardiozerebralen gefässerkrankungen und funduserkrankungen sowie herstellungsverfahren dafür
IL176453A0 (en) Methods and compositions using thalidomide for the treatment and management of central nervous system disorders or diseases
ATE402150T1 (de) Pyrazolaminverbindungen zur behandlung neurodegenerativer erkrankungen
DE602005017762D1 (de) Methode zur behandlung trockener augen und uveitis
BR0306855A (pt) Método para o tratamento de distúrbios cognitivos
WO2005046605A3 (en) Compositions and methods of treating neurological diseases
ATE285773T1 (de) Pharmazeutische zusammensetzungen zur behandlung von neurologischen krankheiten
Estrada et al. Transcranial magnetic stimulation on rodent models
SE0004455D0 (sv) Method for neuron regeneration in the central nervous system
ATE418558T1 (de) Darstellung von 1-aza-2-oxadibenzoäe,hüazulenen und deren verwendung bei der herstellung pharmazeutischer formulierungen zur behandlung und prävention von krankheiten und erkrankungen des zentralen nervensystems

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties